Medical News

New drug applications approved by US FDA as of 01-15 December  2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Thinner photoreceptor layers in the central macula appear indicative of genetic predisposition to age-related macular degeneration (AMD) in healthy Asians, as shown in a study from Singapore.

Treatment with lotilaner ophthalmic solution 0.25% twice daily for 6 weeks is well tolerated by patients with Demodex blepharitis and has no serious adverse effects compared to a vehicle control, according to a study. Moreover, use of this drop results in clinically meaningful outcomes.

For people with type 2 diabetes (T2D) and diabetic retinopathy (DR), bariatric surgery does not appear to confer any risk of DR progression, according to a study.

Use of calcium-channel blockers (CCBs) appears to increase the risk of developing glaucoma, suggests a study. In addition, use of systemic beta blockers is associated with lower intraocular pressure (IOP).

The use of calcium channel blockers (CCBs) may contribute to an increased risk of glaucoma despite CCBs having no effect on intraocular pressure (IOP), according to a large study.

Treatment with dexamethasone implant results in better outcomes for patients with persistent or recurrent uveitic macular edema (ME) at 12 weeks when compared with methotrexate or ranibizumab, a study has shown. The risk of intraocular pressure (IOP), however, is higher with dexamethasone, but elevations to levels of 30 mm Hg or more are rare.

New drug applications approved by US FDA as of 16-31 August 2023 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.